The Global Active Pharmaceutical Ingredients (API) Market: A Frost & Sullivan Briefing on Changing Dynamics
Posted on: Monday, 4 May 2009, 04:30 CDT
(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)
The API market, traditionally dominated by small molecule drugs, is currently witnessing a rapid shift towards biopharmaceuticals. At the same time the manufacturing volume outsourced to contract manufacturing firms is on the rise. As plain vanilla generics continue to get highly competitive, API manufacturers are searching for newer avenues such as the production of high potency API's to differentiate themselves from competition.
Highlights of this briefing include an analysis of the global API market, challenges facing the global API industry, as well as market drivers and restraints, an estimate on the market size, and a look out on emerging trends. The importance of the
This briefing will benefit API manufacturers, contract manufacturing companies, biotechnology as well as pharmaceutical companies, and the financial community wishing to understand the future potential of the API market.
"It is a difficult time for API manufacturers as they continue to battle challenges such as growing competition from low-cost countries and overcapacity. Market participants will increasingly have to rely on strategies such as capability differentiation and consolidation to stay ahead of competition," observes Pharmaceutical & Biotechnology Programme Leader
Frost & Sullivan will hold this conference call at
GIL 2009:
Frost & Sullivan has expanded its flagship Global Congress on Corporate Growth - GIL Global - into several major cities around the world including
For more information you can also visit http://www.frost.com/gilglobal
About Frost & Sullivan:
Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit http://www.frost.com/
Contact: Katja Feick Corporate Communications - Europe P: 0049 (0) 69 77 0 33 43 F: 0049 (0) 69 23 45 66 E: katja.feick@frost.com www.frost.comSOURCE Frost & Sullivan
Source: PR Newswire
Related Articles
- Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award
- Hospital Information Systems (HIS) Markets in Europe: Frost & Sullivan Reveals the Cost, Crunch and the Care Value
- IBM Receives Frost &Amp; Sullivan Award for Global Market Leadership
- EXFO Receives Protocol Technology Innovation Award From Frost &Amp; Sullivan
- Catcher Holdings CEO to Present at Frost &Amp; Sullivan Conference
- IBM Recognized By Frost &Amp; Sullivan As the World Leader of Intrusion Detection and Prevention
- Frost and Sullivan Asia Pacific Market Insights Advances in Breast Imaging, Impact in Asia Pacific
- Anue Systems Wins Frost &Amp; Sullivan Growth Excellence Award
- Generex Biotechnology Receives 2006 North American Frost &Amp; Sullivan Award for Technology Innovation
- Health Hero Network Honored With Frost &Amp; Sullivan Award for Product Innovation
User Comments (0)

RSS Feeds